Iambic Therapeutics (NASDAQ:IAM) Now Covered by Analysts at Citigroup

Research analysts at Citigroup began coverage on shares of Iambic Therapeutics (NASDAQ:IAM) in a report issued on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $22.00 price target on the stock. Citigroup‘s price target points to a potential upside of 116.32% from the company’s previous close.

A number of other analysts have also recently weighed in on IAM. Wall Street Zen raised shares of Iambic Therapeutics to a “hold” rating in a research report on Saturday. Bank of America began coverage on Iambic Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 price target for the company. Three analysts have rated the stock with a Buy rating. According to MarketBeat.com, Iambic Therapeutics has a consensus rating of “Buy” and an average price target of $24.67.

Iambic Therapeutics Stock Performance

Iambic Therapeutics stock opened at $10.17 on Monday. Iambic Therapeutics has a 52-week low of $9.60 and a 52-week high of $25.00.

Insider Buying and Selling

In related news, Director Evan Lockwood Rachlin purchased 718,750 shares of Iambic Therapeutics stock in a transaction that occurred on Friday, October 16th. The shares were purchased at an average cost of $16.00 per share, with a total value of $11,500,000.00. Following the transaction, the director owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. The trade was a 38.45% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Iambic Therapeutics Company Profile